# Sacituzumab Tirumotecan in Previously Treated TROP2-Positive Advanced Biliary Tract Cancer

> **NCT07701122** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Union Hospital, Tongji Medical College, Huazhong University of Science and Technology** · enrollment: 33 (estimated)

## Conditions studied

- Advanced Biliary Tract Cancer(BTC)

## Interventions

- **DRUG:** Sacituzumab Tirumotecan (SKB264)

## Key facts

- **NCT ID:** NCT07701122
- **Lead sponsor:** Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2027-07-01
- **Final completion:** 2028-07-01
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2026-07-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07701122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07701122, "Sacituzumab Tirumotecan in Previously Treated TROP2-Positive Advanced Biliary Tract Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07701122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*